Therapeutic Asset Ratings
188 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
LY3143921
Colorectal Cancer
Cancer Research UK
P1
CC
(43)
LY3143921
Ovarian Serous Cystadenocarcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Non-Small Cell Squamous Lung Carcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Esophageal Squamous Cell Carcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Head And Neck Squamous Cell Carcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Urothelial Carcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Triple-Negative Breast Carcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Malignant Pancreatic Neoplasm
Cancer Research UK
P1
CC
(43)
Aleta-001
Large B-Cell Lymphoma
Cancer Research UK
P1/2
CC
(43)
Aleta-001
B-Cell Non-Hodgkin Lymphoma
Cancer Research UK
P1/2
CC
(43)
Aleta-001
Non-Hodgkin Lymphoma
Cancer Research UK
P1/2
CC
(43)
Atezolizumab
Lung Neoplasm
Cancer Research UK
P1/2
CC
(43)
Chadox1-Magea3-Nyeso
Non-Small Cell Lung Carcinoma
Cancer Research UK
P1/2
CC
(43)
egf816
Gastric Cancer
Cancer Research UK
P2/3
CC
(43)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-31*01 (89.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (85.3%)-IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa
Urinary Bladder Carcinoma
Cancer Research UK
P1/2
CC
(43)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-31*01 (89.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (85.3%)-IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa
Hepatocellular Carcinoma
Cancer Research UK
P1/2
CC
(43)
htl0039732 capsules
Colorectal Neoplasm
Cancer Research UK
P1/2
CC
(43)
htl0039732 capsules
Lung Neoplasm
Cancer Research UK
P1/2
CC
(43)
htl0039732 capsules
Sarcoma
Cancer Research UK
P1/2
CC
(43)
Mva-Magea3
Non-Small Cell Lung Carcinoma
Cancer Research UK
P1/2
CC
(43)
Mva-Nyeso
Non-Small Cell Lung Carcinoma
Cancer Research UK
P1/2
CC
(43)
ucb4594
Colorectal Neoplasm
Cancer Research UK
P1/2
CC
(43)
ucb4594
Ovarian Neoplasm
Cancer Research UK
P1/2
CC
(43)
Enzalutamide
Cervical Cancer
Cancer Research UK
P1/2
CC
(41)
Enzalutamide
Endometrial Carcinoma
Cancer Research UK
P1/2
CC
(41)
Showing 151 to 175 of 188 assets
Previous
Page 7 of 8
Next
